Skip to content
PreclinicalResearch compound

Equipoise (Boldenone Undecylenate)

Injectable muscle-building steroid, once made as a horse medicine; can raise the risk of blood clots and is banned in sport.

Available at

The links above are labelled third-party affiliate links. MolekulaX does not sell and does not verify product quality.

Equipoise (Boldenone Undecylenate) vial

DETAILED OVERVIEW

What is Equipoise (Boldenone Undecylenate)?

Equipoise (Boldenone Undecylenate) is an anabolic steroid, meaning a muscle-building drug similar to testosterone, given as an oil-based injection. It is not approved as a human medicine: it was sold as a veterinary product for horses, but that ended in 2008 and today it exists only on the black market. In the United States it is a controlled substance, in Hungary and Poland it is illegal without a prescription, and in sport it is banned all year round.

Bodybuilders credit it with slow muscle gain and a bigger appetite. It puts little strain on the liver and converts into estrogen less strongly than testosterone does, but the risk of breast growth and water retention cannot be ruled out. Its most serious side effect is an excessive rise in red blood cells, which can cause blood clots, heart attack and stroke. It worsens cholesterol values, can shut down the body's own testosterone production, causes partly irreversible masculinization in women, and must not be used in pregnancy.

Mechanism

Androgen receptor stimulator; converts to estrogen at half the rate of testosterone

Anabolic:Androgenic

100:50

Half-life

14 days (Undecylenate ester)

Onset

48-72 h (IM)

Legal status

Veterinary-only Rx (discontinued 2008), today UGL; Schedule III

Data console

Lab data

Androgenic:Anabolic100:50
AR bindingModerate AR affinity (~50-60% vs testosterone in vitro).
Active half-life~24 h free boldenone (after hydrolysis)
Detection windowBoldenone metabolites (1-androstene-3,17-dione + Δ1-androstene metabolite family) urinary 5-6 months (due to Undecylenate slow clearance; WADA-accredited GC-MS/LC-MS/MS, Schänzer 1996 PMID 8616181).
AromatizationYes – Δ1-testosterone CYP19 substrate at ~50% of Test level; clinically E2 elevation moderate (Pope-Kanayama 2014 PMID 24423981)
HepatotoxicityLow – parent steroid, NOT 17α-alkylated; IM bypasses first-pass. ALT/AST <2x normal for Equipoise-only cycle (Hartgens-Kuipers 2004 PMID 15233599)

Safety

Side effects, stop signs, contraindications

Side effects · 8

  • Polycythemia (abnormally high red blood cell count, hematocrit): boldenone is strongly erythropoietic and can push hematocrit above 54%, raising the risk of thrombosis, stroke and heart attack. This is one of the most clinically significant signature effects of the compound; monitoring and phlebotomy may be required.
  • HPTA suppression and reduced fertility: boldenone suppresses the hypothalamic-pituitary-gonadal axis, lowering LH/FSH, causing endogenous testosterone shutdown, testicular atrophy, reduced sperm count and reversible (sometimes lasting) infertility. Recovery requires PCT, started 3-4 weeks after the last injection due to the long ester.
  • Adverse lipid profile and cardiovascular strain: decreased HDL ("good" cholesterol) and raised LDL, which together with rising hematocrit and possible blood-pressure elevation increases the risk of atherosclerosis and cardiovascular events with longer or repeated cycles.
  • Estrogenic effects from aromatization: boldenone converts to estradiol via CYP19 (about half as strongly as testosterone), which can cause gynecomastia (male breast tissue growth), water retention and elevated estradiol. The risk is lower than with testosterone but not zero; at higher doses an aromatase inhibitor may be needed.
  • Androgenic side effects: acne (especially on the back and shoulders), oilier skin, temporal hair thinning in genetically predisposed individuals, and increased libido or irritability. Although boldenone converts to DHT more weakly than testosterone, androgenic effects can appear from moderate doses.
  • Virilization in women: voice deepening, increased body hair growth, clitoral enlargement, menstrual disturbances and acne. Some virilizing signs (voice change, clitoral growth) can be permanent or irreversible, making this compound high-risk for women.
  • Injection-site reactions (injectable depot): pain, swelling, redness or a lump at the injection site (post-injection pain, PIP), plus risk of sterile or infectious abscess with improper, non-sterile technique. The viscosity of the oily undecylenate ester can increase local irritation.
  • Psychological and behavioral effects: mood swings, increased aggression or irritability, and risk of developing AAS dependence with repeated cycles; the post-cycle hypogonadal state can cause depressive symptoms.

Contraindications · 7

  • Pre-existing polycythemia / high hematocrit (>54%): absolute contraindication. The strong erythropoietic effect of Equipoise further raises red cell mass, creating life-threatening risk of thrombosis, stroke or heart attack.
  • Pregnancy and breastfeeding: contraindicated due to fetal virilization and teratogenic risk. The compound can pass into breast milk and cause irreversible developmental harm.
  • Hormone-sensitive cancers: prostate cancer or known/suspected breast cancer (including in men). Androgenic stimulation can accelerate progression of these tumors, so use is prohibited.
  • Cardiovascular disease or high risk: existing coronary artery disease, uncontrolled hypertension, prior thrombotic event or severe dyslipidemia. The combination of HDL decline, rising hematocrit and blood-pressure elevation compounds the risk.
  • Competitive (WADA / drug-tested) athletes: banned year-round (S1.1.a), and boldenone metabolites remain detectable in urine for 5-6 months due to the long undecylenate ester. Use results in a career-ending anti-doping violation.
  • Anticoagulant therapy (e.g. warfarin): boldenone can potentiate the effect of blood thinners, creating a bleeding risk; contraindicated without close INR monitoring.
  • Adolescents and youths with incomplete bone growth: androgens can prematurely close the epiphyseal growth plates, irreversibly stunting final adult height.

Related Performance Compounds

Same therapeutic category

Studies

Related research and clinical findings

Telegram

Have a question about Equipoise (Boldenone Undecylenate)?

Reach out to an advisor on Telegram. Performance compounds are presented with a harm-reduction approach, based on peer-reviewed evidence.

Personalized consultation

Want a detailed conversation tailored to your data?

Fill out the prep intake form (your goals, training and health data), and the advisor prepares from it to give genuinely personalized guidance.

Fill out the form

~5–7 min · prep questionnaire · confidential · GDPR-compliant

MolekulaX Editorial Team·Source-verified · PubMed · FDA · EMA
Updated: October 14, 2026

The information here is for educational and scientific purposes only. Performance-enhancing compounds (AAS, prohormones, stimulants, doping agents) are illegal without prescription in Hungary and most of the EU, and carry serious health and legal risks. WADA bans them in competitive sport. This is NOT a usage guide, and we do not encourage any illegal use. If you do use them, medical supervision and regular bloodwork are ESSENTIAL. Severe endocrine, cardiovascular, hepatic and psychiatric side effects are possible.